FDA Approves Zidesamtinib for ROS1-positive Non-Small Cell Lung Cancer By Ogkologos - September 16, 2026 17 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the ARROS-1 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Welcomes the European Parliament’s (EP) Call for a Sustainable Cancer Workforce to Deliver Quality Care for Patients with Cancer ESMO Welcomes the Inclusion of Tobacco Provisions in European Parliament’s Report on Cardiovascular Diseases and Calls for Additional Measures to Prevent Cancer Perioperative Durvalumab Continues to Show Clinical Benefit in Patients with Resectable Stage IIA to IIIB NSCLC MOST POPULAR Spotlight On: Exercise Physiologists in Cancer Care November 16, 2023 Qué saber al buscar información sobre el cáncer en línea: perspectiva... August 11, 2022 Cancer Drug Lynparza Found to Lower Risk of Death and Recurrence... June 4, 2021 Measurable Residual Disease Adapted Consolidation Strategy After Quadruplet Induction Therapy for... July 8, 2025 Load more HOT NEWS What to Know About At-Home DNA Tests for Detecting Cancer Risk Teclistamab Results in a High Rate of Deep and Durable Response... Food for Thought: A Fresh Perspective on Nutrition Active Surveillance for Low-Risk Prostate Cancer Continues to Rise
